Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.860
-0.190 (-4.69%)
May 28, 2026, 3:53 PM HKT
Market Cap1.41B -75.2%
Revenue (ttm)37.13M -53.6%
Net Income-146.26M
EPS-0.40
Shares Out 364.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,600
Open3.850
Previous Close4.050
Day's Range3.850 - 3.940
52-Week Range2.400 - 10.580
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJun 4, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 131
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2563
Full Company Profile

Financial Performance

In 2025, HKG:2563's revenue was 33.36 million, a decrease of -53.57% compared to the previous year's 71.87 million. Losses were -131.44 million, -8.58% less than in 2024.

Financial numbers in CNY Financial Statements